ND Committee Review
Internal Medical Policy Committee 1-22-2020 Added additional NCCN indications and formatting changes, updated FDA statement, added additional diagnosis
Internal Medical Policy Committee 1-19-2021 Annual review, no clinical content change
Internal Medical Policy Committee 7-22-2021 Added additional FDA indication and NCCN recommendations, removed five diagnosis codes
Internal Medical Policy Committee 5-24-2022 Removed NCCN recommendations and added this statement "Ramucirumab (Cyramza) may be considered medically necessary for treatment of any of the current category 1 or 2A NCCN recommendations.", removed diagnosis codes (C17.0, C17.1, C17.2, C17.8, C17.9, D37.1, D37.8, D37.9, Z85.00, Z85.01, Z85.028, Z85.038, Z85.068), updated the experimental/investigational statement